close

Elder Pharma

Know More
NSEBSE

113.150.00 (0.00%)

4th Mar 2015

416.60000.00 (0.00%)

2nd Jul 2007

BSE : 532322

NSE : ELDERPHARM

Sector :

ISIN Code :

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Jul 02 2007 | 12:00 AM IST

Market Cap (₹ Cr)

NaN

Turnover (₹ Cr)

NaN

Volume (Shares)

16527

52-WK High

117.00

52-WK High Date

02 Oct 2023

52-WK Low

0.00

52-WK Low Date

02 Oct 2023

All Time High

All Time High Date

02 Oct 2023

All Time Low

All Time Low Date

02 Oct 2023

Elder Pharma

Elder Pharmaceuticals Ltd is one of the fastest growing pharmaceutical companies in India. The company's principal activities include the manufacturing and marketing of prescription pharmaceutical brands surgical and medical devices. They are engaged in the manufacture of a wide range of pharmaceutical product through research and development and also in the manufacturing and marketing of diverse products through licensing agreements with international pharmaceutical companies. They are also engaged in the manufacturing of active pharmaceutical ingredients. Elder Pharmaceuticals Ltd was incorporated on April 2 1983 in Maharashtra. The company started their commercial activities in the year 1988. In the year 1989 they commissioned their first factory in Navi Mumbai. The company was converted into a public limited company in August 1998. Over the years the company launched the medicines either through their own research or through alliances with global companies.The company entered into strategic alliances with a number of international pharmaceutical entities for marketing their products in India and overseas international acquisitions have strengthened and enabled the company to become a true-global pharmaceutical company. They made the tie up with Haw Par Singapore during the year 1994 and Fujisawa during the year 1998.During the year 2000-01 the company entered into joint venture agreement with Stiefel Laboratories Inc. Also they made a tie up with Paul Hartmann of Germany for marketing their incotinence and wound healing in India.During the year 2002-03 the company made a tie up with an American company namely Blistex Inc for license manufacturing and distribution of their Lip Care products. The company entered into technical/ marketing collaborations with Covex and Ferrer of Spain for their products for Cognitive disorders Cerebral strokes and Head injuries Tanabe Seiyaku and Fujisawa of Japan for their products for Hypertension and Heart Failure and TRB Chemeica of Switzerland for their product for Osteoarthritis.During the same year the company entered into new joint venture agreement with the Universal Group of Companies Nepal for setting up a pharmaceutical formulations plant in Nepal. In March 2003 they started their operation in their Bulk Drug plant at Patalganga.During the year 2004-05 the company acquired an international brand 'Tobraneg' from Ely Lilly and company of USA at a price of Rs 172.50 lakh. During the year 2005-06 they commissioned one of their new manufacturing units at Sela Qui in Uttarakhand which is equipped to manufacture tablets and capsules. The company introduced 'Somazina' a neuroprotector during the year.During the year 2006-07 the company introduced Eldervit ZC Redirinse Nedge Bonviva and Deviron in the market. Also they entered with the alliances with Roche of Switzerland for their product 'Bonivini' Daiwa of Japan for their product 'Biobran' & 'NKCP' Enzymotec of Isreal for their product 'Cardiabeat' and Almirall of Spain for the product 'Cinitapride'.The company commenced commercial production of manufacturing of topical formulation in their plant at Paonta Sahib in Himachal Pradesh during the year. They commissioned a betalactum plant in Nepal through a joint venture with Universal Pharmaceuticals. The company also entered into joint venture with Vincom Pharmaceuticals in Ghana for Oral Liquid dosages. In January 2007 the company established a wholly owned subsidiary called Elder International FZCO in the Jebel Ali Free Trade Zone Dubai.During the year 2007-08 the company got associated with Cymbiotics of California USA for marketing six of their patented products for Diabetes Chrobnic pain Skin Care etc. and Gnosis of Italy for marketing of 'Sampure'. They formed a wholly owned subsidiary in Cyprus by the name Somerta Holdings Co Ltd with a capital of Euro 5000.The company through their wholly owned subsidiary Elder International FZCO acquired a 21% stake in Neutrahealth PLC an AIM London Stock Exchange listed company and also established a wholly owned subsidiary in Bulgaria by the name 'Elder Biomeda EDA' with the object of acquiring 100% stake in three Biomeda Group companies for the total investment of Euro 3.12 million.The company was awarded Amity Corporate Excellence Award for the year 2008 and Frost & Sullivan Market Leadership Award for 'Shelcal' for the year 2008. They have been named in the Forbes list of 'Asia's 200 Best under a billion' over a period of three years.In November 2008 the company entered into a deal with Japan's Daiwa Pharmaceuticals Co Ltd for manufacturing and marketing of some of their products in India. Also they acquired 100% stake in three Bulgarian pharma companies through their wholly owned Bulgarian subsidiary Elder Biomeda EAD.

Elder Pharma - Key Fundamentals

PARAMETER VALUES
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Year Low/High

0.00

0.00

All time Low/High

20.35

474.00

Share Price Returns

Period BSENSE SENSEXNIFTY
%%%
This stock has been delisted. Data presented here are the latest available.

Bulk/ Block

ALL
NSE
BSE
ALL
BUY
SELL
DateClient NameExchangeTransactionQuantityPrice
05-01-2015MILLENNIUM STOCK BROKING PVT LTDBSESELL198227161.51
05-01-2015MILLENNIUM STOCK BROKING PVT LTDBSEBUY198280161.38
25-03-2014MONET SECURITIES P LTDBSEBUY123310194.10
25-03-2014SUPREME WOOD PRODUCTS PVT. LTDBSESELL123310194.10
01-01-2014CROSSEAS CAPITAL SERVICES PRIVATE LIMITEDBSESELL107283253.75
01-01-2014CROSSEAS CAPITAL SERVICES PRIVATE LIMITEDBSEBUY107501254.78
13-12-2013CROSSEAS CAPITAL SERVICES PRIVATE LIMITEDBSEBUY208940315.71
13-12-2013CROSSEAS CAPITAL SERVICES PRIVATE LIMITEDBSESELL208940316.51
05-11-2012ELDER PHARMA EMPLOYEES WELFARE TRUSTBSESELL150000302.37
28-07-2011ALMONDZ CAPITAL & MANAGEMENTBSESELL103500411.05

Load More

This stock has been delisted. Data presented here are the latest available.
This stock has been delisted. Data presented here are the latest available.

Corporate Action

Announcement DatePurposeFromToRemarks
Data Not Found

Price History

Search for Price History

DateOpenHighLowCloseSharesTrades
Data Not Found

Load more

Company Info

Company Information

Managing Director & CEO : Alok Jagdish Saxena

Director : Edoardo Carlo Richter

Company Secretary : Vijendra Jain

Additional Director : Ravani Mohammed Abdul Khader

Additional Director : Kader Mohammed Davawala